An mRNA vaccine combined with Keytruda reduced melanoma recurrence risk by 49% in a trial. After five years, 68.8% of patients remained cancer-free. The personalized vaccine targets each patient's tumor, offering hope for preventing advanced skin cancer.
Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk
✨ Enjoying this article? ✨
📱 Get more with the NewsNuggs iOS App →